Results 121 to 130 of about 15,404 (212)

Comparison of sitagliptin monotherapy with combination therapy

, 2018
Çalışmamızda sitagliptinin monoterapide ve kombinasyon (metformin veya pioglitazon) tedavilerinde kullanımlarının glisemik kontrol, lipid profili ve insülin direnci üzerine etkilerinin karşılaştırılması amaçlanmıştır.
Şişman, Pınar
core  

Effect of Sitagliptin and Vitamin D3 on Secretion of IL-6 and TNF-α Inflammatory Factors in Patients with Type 2 Diabetes

پزشکی بالینی ابن سینا, 2018
Background and Objective: Diabetes mellitus is one of the most commonly reported diseases that is associated with insulin resistance and increased blood glucose levels.
Elham Mahabadi-Ashtiyani, Vida Sheikh, Shiva Borzouei, Iraj Salehi, Mahdi Alahgholi-Hajibehzad   +4 more
doaj  

Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes

, 2015
BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease.
Standl, Eberhard, Pencina, Michael J, Garg, Jyotsna, Josse, Robert, Lachin, John M, Peterson, Eric D, Armstrong, Paul W., Lachin, John M., Peterson, Eric D., Korn, Scott, Engel, Samuel S, Suryawanshi, Shailaja, Armstrong, Paul W, TECOS Study Group, Bethel, M Angelyn, McGuire, Darren K., Buse, John B., de Werf, Frans Van, LEMBO, Giuseppe, Buse, John B, Bethel, M. Angelyn, Stein, Peter P, Engel, Samuel S., Van de Werf, Frans, Koglin, Joerg, Stein, Peter P., Holman, Rury R., Kaufman, Keith D., Holman, Rury R, Green, Jennifer B., Pencina, Michael J., Green, Jennifer B, McMurray, John, McGuire, Darren K, Kaufman, Keith D   +34 more
core   +1 more source

Clinical utility and patient considerations in the use of the sitagliptin-metformin combination in Chinese patients

Patient Preference and Adherence, 2015
Qiang Du, Yan-Jun Wang, Sheng Yang, Ping HanDepartment of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People’s Republic of ChinaAbstract: The prevalence of diabetes mellitus (DM) continues to increase each ...
Du Q, Wang YJ, Yang S, Han P
doaj  

Sitagliptin-induced hyperthyroidism: a case report

Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is commonly used to manage type 2 diabetes mellitus (T2DM). Although generally considered safe, recent studies suggest a potential role of DPP-4 inhibitors in modulating immune responses ...
Kauser Usman, Feras M. Almarshad, Yusuf Jamal, Dushad Ram, Jamal Arif   +4 more
core   +1 more source

Eyedrop Administration of DPP-4 Inhibitors: A New Strategy for Treating Early Stages of Diabetic Retinal Disease. [PDF]

Int J Mol Sci
Ramos H, Simó-Servat O, Hernández C, Simó R.   +3 more
europepmc   +1 more source

Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T2DM: Insights From a Systematic Review and Meta-Analysis. [PDF]

Endocrinol Diabetes Metab
Ashraf S, Burhan M, Sarwar S, Ali A, Ahsan A, Ashraf S, Javaid H, Irfan H, Awan MHN, Singh A, Ayalew BD.   +10 more
europepmc   +1 more source

Low dose of sitagliptin: effectively prevent liver aGVHD and accelerate neutrophil engraftment. [PDF]

Ann Hematol
Liu M, Zhong Z, Wang H.
europepmc   +1 more source

Sitagliptin Modulates Functional and Phenotypic Properties of Human Neutrophils Under Normal- and High-Glucose Conditions In Vitro. [PDF]

Molecules
Mališ V, Drakul M, Rakočević S, Kozić L, Dubovina A, Popović D, Bokonjić D, Mihajlović D, Čolić M.   +8 more
europepmc   +1 more source

Association Between Dipeptidyl Peptidase-4 Inhibitor Use and Acute Kidney Injury in Patients With Diabetes Mellitus: A Disproportionality Analysis Based on the FAERS. [PDF]

In Vivo
Ohyama K, Takahashi T, Akiyama S, Hori Y.   +3 more
europepmc   +1 more source